Investor Presentaiton
GIVING INDIA THE EDGE IN PHARMACEUTICALS
COST LEADERSHIP
DIVERSE RANGE OF PRODUCTS
GLOBALLY RECOGNIZED CAPABILITIES
LEADER IN DRUG APPLICATIONS
LEADER IN MEDICAL TOURISM
FDI
CONDUCIVE PATENT REGIME
Cost of production of pharmaceuticals in India is -60% lower than that of US and almost half of that of Europe.
Over 60,000 generic brands across 60 therapeutic categories are manufactured in India.
Out of all drug master filings from India, 49% are registered in the USA.
Indian pharmaceutical industry accounts for the 2nd largest number of Abbreviated New Drug
Applications (ANDAs).
The value of medical tourism in India is expected to reach US$ 9 billion by 2020
Up to 100% FDI is allowed for manufacturing of medical devices/equipment.
Patents for branded molecules with cumulative global sales of over US$251 billion are expected to
expire between 2018 & 2024.View entire presentation